Ulcerative colitis
Conditions
Interventions
None listed
Sponsors
Wakayama medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. male or female, over 18 years old 2. diagnosed with ulcerative colitis at least 3 months prior to obtaining consent 3.The patient is taking Xeljanz. 4.Consent can be obtained from the individual.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women. 2.Patients with a history of hypersensitivity to Xeljanz. 3.Patients who have previously undergone surgical treatment for ulcerative colitis. 4.Patients who are dependent on parenteral nutrition. 5.Patients with Child-pugh Class C hepatic impairment. 6.Patients with active tuberculosis or untreated latent tuberculosis. 7.Patients with a history of malignancy within the last 5 years. 8.Patients with a history of opportunistic infections or immunodeficiency syndromes. 9.Patients with mental illness. 10.Patients who are judged by the physician to be unsuitable for the safe conduct of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between blood CRP concentration and tofacitinib concentration, association between blood IL-6 concentration and tofacitinib concentration, association between CYP3A4/5 gene polymorphism and tofacitinib concentration, association between duration of tofacitinib use and tofacitinib concentration, association between blood tofacitinib concentration and Lichtiger index, association between blood tofacitinib concentration and the frequency of side effects | — |
Countries
Japan
Contacts
Public ContactMasaki Takao
Wakayama medical university second department of internal medicine
Outcome results
None listed